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OBJECTIVE: beta-blockers have provided evidence of improv-
ing survival in chronic heart failure patients. Speciﬁcally, the
Cardiac Insufﬁciency Bisoprolol Study II has shown a signiﬁcant
reduction in mortality and morbidity among patients with mod-
erate to severe chronic heart failure treated with bisoprolol. Our
aim was to investigate the economic consequence of bisoprolol
therapy in chronic heart failure patients in Italy. METHODS:
Data were derived from the Cardiac Insufﬁciency Bisoprolol
Study II trial. We conducted a cost-effectiveness analysis, com-
paring standard care with bisoprolol vs. standard care with
placebo in the perspective of the Italian National Health Service.
We identiﬁed and quantiﬁed medical costs: drug costs according
to the Italian National Therapeutic Formulary; specialist visits
for initiation and up-titration of bisoprolol therapy and hospi-
talizations were quantiﬁed based on the Italian National Health
Service tariffs (2005). Effects were measured in terms of mor-
tality and morbidity reduction (number of deaths, life years
gained and frequency of hospitalizations). We considered an
observational period of 1.3 years, i.e. the average follow-up
recorded in the trial. Discounting was not performed because of
the relatively short follow-up of patients. We conducted one and
multi-way sensitivity analyses on unit cost and effectiveness. We
also conducted a threshold analysis. RESULTS: The overall cost
of care per 1.000 patients treated for 1.3 years was estimated in
€2,075,548 in the bisoprolol group and in €2,396,265 in the
placebo group, resulting in a net saving of €320,718. The
number of additional patients alive with bisoprolol was 55 per
1000 patients; the number of life years gained was 36 at 1.3 year.
CONCLUSIONS: Bisoprolol therapy is dominant since it is 
both less costly and more effective than standard care. Results
of sensitivity analysis showed that bisoprolol therapy remains
dominant even to changes in unit cost of drug and 
hospitalizations.
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OBJECTIVES: To compare two different methods in evaluating
cost-effectiveness (CE) of candesartan for patients with chronic
heart failure (CHF) in Germany based on the CHARM (Can-
desartan in Heart failure: Assessment of Reduction in Mortality
and Morbidity)-programme. METHODS: For both analyses, CE
was measured by calculating incremental cost-per-avoided-event.
Two analytical approaches were chosen examining two treat-
ment groups of the CHARM-programme: “Added” (low left
ventricular ejection fraction (LVEF <40%) and “Alternative”
(LVEF <40% and intolerant of an ACE inhibitor). The ﬁrst
approach calculated average costs per patient based on all car-
diovascular events happened (Hospital admissions due to wors-
ening heart failure, cardiovascular deaths, and cardiovascular
procedures). Absolute risk reduction (ARR) to avoid/delay an
event also was derived from all events occurring in the clinical
trial. The second approach simulated the real life situation of
patients with CHF in a Markov-analysis over 12 periods (3
years). Risk tables on mortality and morbidity were derived from
Kaplan-Meier-Curves of the CHARM-protocols. ARR was
determined through a Monte-Carlo-Simulation for a cohort of
1276 patients. For both approaches, cost calculation was per-
formed from the perspective of the German statutory health
insurance (SHI). Base year for costing was 2004. Only direct
costs (drug, hospital, general practitioner, specialist, ambulance,
rehabilitation) were considered. RESULTS: In the case-based-
costing-approach, the incremental costs to prevent/delay a car-
diovascular death or a hospital admission were €516 (“Added”)
and €1210 (“Alternative”). The Markov-Analysis presented 
corresponding ratios of €2117 (“Added”) and €2814 (“Alterna-
tive”). Sensitivity analysis on costs, discounting rates and effects
size showed the robustness of both models’ results. CONCLU-
SIONS: Both analyses showed the cost-effectiveness of can-
desartan for patients with chronic heart failure. Conducting a
simulation that considers real-life-conditions leads to higher
ratios, but gives a more precise estimate of the cost-effectiveness
of candesartan in a long-term-perspective.
PCV23
ECONOMIC EVALUATION OF VALSARTAN IN PATIENTS WITH
CHRONIC HEART FAILURE IN THE HUNGARIAN HEALTH
CARE SETTING
Kósa J1, Reed SD2, Radeva J2
1Novartis Hungary, Budapest, Pest, Hungary; 2Duke Clinical Research
Institute, Durham, North Carolina, USA
OBJECTIVES: To estimate the costs, beneﬁts, and cost-
effectiveness of valsartan as a treatment of chronic heart failure
(CHF) in Hungary. METHODS: A country-speciﬁc economic
analysis was undertaken by combining within-trial efﬁcacy and
resource data from the Valsartan Heart Failure Trial (Val-HeFT)
with Hungarian cost estimates. Unit cost estimates were obtained
from ofﬁcial data sources of the National Health Found in
Hungary and were adjusted to 2004 Hungarian forints. Total
within-costs were estimated for hospitalizations, inpatient and
outpatient physician services, ambulance transportation, deaths
outside the hospital, and outpatient cardiovascular medications.
We estimated life expectancy using two different methods, by
taking the reciprocal of the mortality rate observed in the trial
and based on the percentages of patients who had died during
the trial. We compared within-trial inpatient days and number
of hospitalizations using a negative binomial model adjusting 
for follow up. T-tests were used to compare within-trial costs.
We also estimated the incremental cost per life year saved. 
Analyses were conducted for subgroups identiﬁed in Val-Heft.
RESULTS: The net incremental cost in the valsartan group was
208,766Ft over 23 months of follow-up. Over the course of the
trial, patients treated with valsartan had on average a net incre-
mental cost of 183,619Ft. Among patients not treated with an
ACE inhibitor at baseline, the incremental cost-effectiveness
ratio was 402,438Ft per life-year saved when we estimated life
expectancy by taking the reciprocal of the mortality rate
observed in the trial. When we estimated life expectancy using
the daily hazard rate, the incremental cost-effectiveness ratio was
450,597Ft per life-year saved. CONCLUSIONS: Valsartan pro-
vided clinical beneﬁts at a mean incremental cost of 108,921Ft
per year during the trial. In patients not taking ACE inhibitors,
valsartan was economically attractive, increasing survival for a
reasonable cost.
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OBJECTIVES: The aim of the study was to assess the incre-
mental cost-per life-year saved with Eplerenone, an aldosterone
antagonist, alongside with standard treatment for patients with
post AMI heart failure, versus standard treatment alone.
